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 Side chain theory of immunity
 Antibodies - magic bullets 1899/1906
Therapy of Non Hodgkin’s Lymphoma (NHL) 
Bexxar ®
Tositumomab labeled with I-131
Zevalin ®
Ibritumomab tiuxetan labeled with Y-90
Are antibodies really “magic bullets”?
Therapy of Non Hodgkin lymphoma (NHL)
 Rituximab (Rituxan®), 
Obinutuzumab (Gazyva™), 
Ofatumumab (Arzerra®), 
Ibritumomab tiuxetan (Zevalin®)
 NHL is sensitive to radiation
 can be curative in early stage NHL
Design of new 
radiopharmaceuticals
 Antibody selection
 Suitable radionuclide
 Formulation issues
 Stability issues
•
•
 Pre-clinical studies
•
•
 Clinical studies
Selection of antibodies
Murine
Chimeric
Humanized
Human
 antibody fragments
 tumor pretargeting
 type of administration 
Target?
Receptor?
Affinity?
Immunogenicity?
Radioisotope selection
Diagnosis?
Therapy? 
Properties?
Availability?
SPECT/PET ?
Rituximab
p-SCN-Bn-DOTA
p-SCN-Bn-DTPA 
1B4M-DTPA
B- cell Rituximab
177Lu 
Why 177Lu ?
90 Yttrium 131 Iodine 177 Lutetium
Energy 
emitted
Beta (2.3 MeV)
Beta (0.6 MeV)
Gamma (0.36 
MeV)
Beta (max 0.5 
MeV) 
Gamma 208 keV
(11%)
Half-life 64 hours 8.04 days 6.71 days
Mean path-
length
3.9 mm 1 mm 0.7 mm
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Lyophilisation
Lyophilized kits 
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Conjugation
Radiolabeling of kits &
physicochemical evaluation
 reconstitution in 0.9% NaCl, in the presence of acetate 
ions at pH 7.0 with Lutetium-177 with specific activity of 
555 GBq/mg, at room temperature
177Lu 
177Lu-1B4M-DTPA-rituximab
1177Lu-DTPA-rituximab
177Lu-DOTA-rituximab
Radiolabeling with 177Lu after reconstitution of lyophilisates
SE – HPLC / ITLC 
 High radiochemical purity
Conclusion
 Lyophilized kits, ready to label with 177Lu
 Candidates for pre-clinical cell and animal studies
 Candidates for new ready to label rituximab for NHL 
therapy
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